{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":28,"n_cols":5,"rows_kept":28,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[14,2,14,3],[16,2,16,3],[17,2,17,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911020248403321"]
[null,null,"Titolo",null,"Proteomics in drug research / / edited by Michael Hamacher ... [et al.]"]
[null,null,"Pubbl/distr/stampa",null,"Weinheim, : Wiley-VCH"]
[{"$nulls":4},"Chichester, : John Wiley [distributor], c2006"]
[null,null,"ISBN",null,"9786610723430"]
[{"$nulls":4},"9781280723438"]
[{"$nulls":4},"1280723432"]
[{"$nulls":4},"9783527608232"]
[{"$nulls":4},"3527608230"]
[{"$nulls":4},"9783527607945"]
[{"$nulls":4},"3527607943"]
[null,null,"Descrizione fisica",null,"1 online resource (386 p.)"]
[null,null,"Collana",null,"Methods and principles in medicinal chemistry ; ; v. 28"]
[null,null,"Disciplina",null,"572.6"]
[null,null,"Soggetti",null,"Proteomics"]
[{"$nulls":4},"Drugs - Research"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Proteomics in Drug Research; Contents; A Personal Foreword; Preface; List of Contributors; I Introduction; 1 Administrative Optimization of Proteomics Networks for Drug Development; 1.1 Introduction; 1.2 Tasks and Aims of Administration; 1.3 Networking; 1.4 Evaluation of Biomarkers; 1.5 A Network for Proteomics in Drug Development; 1.6 Realization of Administrative Networking: the Brain Proteome Projects; 1.6.1 National Genome Research Network: the Human Brain Proteome Project; 1.6.2 Human Proteome Organisation: the Brain Proteome Project; 1.6.2.1 The Pilot Phase; References"]
[{"$nulls":4},"2 Proteomic Data Standardization, Deposition and Exchange2.1 Introduction; 2.2 Protein Analysis Tools; 2.2.1 UniProt; 2.2.2 InterPro; 2.2.3 Proteome Analysis; 2.2.4 International Protein Index (IPI); 2.2.5 Reactome; 2.3 Data Storage and Retrieval; 2.4 The Proteome Standards Initiative; 2.5 General Proteomics Standards (GPS); 2.6 Mass Spectrometry; 2.7 Molecular Interactions; 2.8 Summary; References; II Proteomic Technologies; 3 Difference Gel Electrophoresis (DIGE): the Next Generation of Two-Dimensional Gel Electrophoresis for Clinical Research; 3.1 Introduction"]
[{"$nulls":4},"3.2 Difference Gel Electrophoresis: Next Generation of Protein Detection in 2-DE3.2.1 Application of CyDye DIGE Minimal Fluors (Minimal Labeling with CyDye DIGE Minimal Fluors); 3.2.1.1 General Procedure; 3.2.1.2 Example of Use: Identification of Kinetic Proteome Changes upon Ligand Activation of Trk-Receptors; 3.2.2 Application of Saturation Labeling with CyDye DIGE Saturation Fluors; 3.2.2.1 General Procedure; 3.2.2.2 Example of Use: Analysis of 1000 Microdissected Cells from PanIN Grades for the Identification of a New Molecular Tumor Marker Using CyDye DIGE Saturation Fluors"]
[{"$nulls":4},"3.2.3 Statistical Aspects of Applying DIGE Proteome Analysis3.2.3.1 Calibration and Normalization of Protein Expression Data; 3.2.3.2 Detection of Differentially Expressed Proteins; 3.2.3.3 Sample Size Determination; 3.2.3.4 Further Applications; References; 4 Biological Mass Spectrometry: Basics and Drug Discovery Related Approaches; 4.1 Introduction; 4.2 Ionization Principles; 4.2.1 Matrix-Assisted Laser Desorption/Ionization (MALDI); 4.2.2 Electrospray Ionization; 4.3 Mass Spectrometric Instrumentation; 4.4 Protein Identification Strategies"]
[{"$nulls":4},"4.5 Quantitative Mass Spectrometry for Comparative and Functional Proteomics4.6 Metabolic Labeling Approaches; 4.6.1 (15)N Labeling; 4.6.2 Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC); 4.7 Chemical Labeling Approaches; 4.7.1 Chemical Isotope Labeling at the Protein Level; 4.7.2 Stable Isotope Labeling at the Peptide Level; 4.8 Quantitative MS for Deciphering Protein-Protein Interactions; 4.9 Conclusions; References; 5 Multidimensional Column Liquid Chromatography (LC) in Proteomics - Where Are We Now?; 5.1 Introduction; 5.2 Why Do We Need MD-LC/MS Methods?"]
[{"$nulls":4},"5.3 Basic Aspects of Developing a MD-LC/MS Method"]
[null,null,null,"Sommario/riassunto","From skillful handling of the wide range of technologies to successful applications in drug discovery -- this handbook has all the information professional proteomics users need. Edited by experts working at one of the hot spots in European proteomic research, the numerous contributions by experts from the pharmaceutical industry and public proteomics consortia to provide the necessary perspective on current trends and developments in this exciting field.Following an introductory chapter, the book moves on to proteomic technologies, such as protein biochips, protein-protein interaction"]